AAAAAA

   
Results: 1-7 |
Results: 7
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2 '-deoxycytidine
Authors: Lubbert, M Wijermans, P Kunzmann, R Verhoef, G Bosly, A Ravoet, C Andre, M Ferrant, A
Citation: M. Lubbert et al., Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2 '-deoxycytidine, BR J HAEM, 114(2), 2001, pp. 349-357
Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS
Authors: de Witte, T Suciu, S Verhoef, G Labar, B Archimbaud, E Aul, C Selleslag, D Ferrant, A Wijermans, P Mandelli, F Amadori, S Jehn, U Muus, P Boogaerts, M Zittoun, R Gratwohl, A Zwierzina, H Hagemeijer, A Willemze, R
Citation: T. De Witte et al., Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS, BLOOD, 98(8), 2001, pp. 2326-2331
Intensive chemotherapy followed by stem cell transplantation for the treatment of myelodysplastic syndromes
Authors: de Witte, T Suciu, S Verhoef, G Labar, B Archimbaud, E Aul, C Selleslag, D Ferrant, A Wijermans, P Mandelli, F Amadori, S Jehn, U Muus, P Demuynck, H Dardenne, M Zittoun, R Willemze, R Gratwohl, A Apperley, J
Citation: T. De Witte et al., Intensive chemotherapy followed by stem cell transplantation for the treatment of myelodysplastic syndromes, HEMAT BLOOD, 40, 2001, pp. 649-654
Low-dose 5-aza-2 '-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
Authors: Wijermans, P Lubbert, M Verhoef, G Bosly, A Ravoet, C Andre, M Ferrant, A
Citation: P. Wijermans et al., Low-dose 5-aza-2 '-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients, J CL ONCOL, 18(5), 2000, pp. 956-962
Very mild pathology in a case of Hb S/beta(0)-thalassemia in combination with a homozygosity for the alpha-thalassemia 3.7 kb deletion
Authors: Kerkhoffs, JL Harteveld, CL Wijermans, P van Delft, P Haak, HL Bernini, LF Giordano, PC
Citation: Jl. Kerkhoffs et al., Very mild pathology in a case of Hb S/beta(0)-thalassemia in combination with a homozygosity for the alpha-thalassemia 3.7 kb deletion, HEMOGLOBIN, 24(3), 2000, pp. 259-263
Peripheral blood stem cell transplantation as an alternative to autologousmarrow transplantation in the treatment of acute myeloid leukemia?
Authors: Vellenga, E van Putten, WLJ Boogaerts, MA Daenen, SMGJ Verhoef, GEG Hagenbeek, A Jonkhoff, AR Huijgens, PC Verdonck, LF van der Lelie, J Schouten, HC Gmur, J Wijermans, P Gratwohl, A Hess, U Fey, MF Lowenberg, B
Citation: E. Vellenga et al., Peripheral blood stem cell transplantation as an alternative to autologousmarrow transplantation in the treatment of acute myeloid leukemia?, BONE MAR TR, 23(12), 1999, pp. 1279-1282
Comparison of single and dual-platform assay formats for CD34(+) haematopoietic progenitor cell enumeration
Authors: Gratama, JW Braakman, E Kraan, J Lankheet, P Levering, WHBM Van den Beemd, MWM Van der Schoot, CE Wijermans, P Preijers, F
Citation: Jw. Gratama et al., Comparison of single and dual-platform assay formats for CD34(+) haematopoietic progenitor cell enumeration, CLIN LAB H, 21(5), 1999, pp. 337-346
Risultati: 1-7 |